Home » Stocks » Synlogic

Synlogic, Inc. (SYBX)

Stock Price: $2.27 USD 0.03 (1.12%)
Updated Aug 4, 2020 3:19 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 74.38M
Revenue (ttm) 1.99M
Net Income (ttm) -54.26M
Shares Out 32.84M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $2.27
Previous Close $2.24
Change ($) 0.03
Change (%) 1.12%
Day's Open 2.22
Day's Range 2.22 - 2.29
Day's Volume 81,953
52-Week Range 1.35 - 5.82

More Stats

Market Cap 74.38M
Enterprise Value n/a
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.84M
Float 16.98M
EPS (basic) -1.67
EPS (diluted) -1.67
FCF / Share -2.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 329,360
Short Ratio 0.93
Short % of Float 2.10%
Beta 2.03
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 37.45
PB Ratio 0.53
Revenue 1.99M
Operating Income -57.11M
Net Income -54.26M
Free Cash Flow -76.09M
Net Cash 90.80M
Net Cash / Share 2.76
Gross Margin 111.98%
Operating Margin -2,875.63%
Profit Margin -2,731.90%
FCF Margin -3,831.07%
ROA -22.58%
ROE -42.67%
ROIC -29.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$7.25*
(220.09% upside)
Low
2.00
Current: $2.27
High
13.00
Target: 7.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue2.222.522.440.44----
Revenue Growth-11.75%3.11%450.45%-----
Gross Profit2.222.522.440.44----
Operating Income-54.41-51.23-40.82-20.96-25.03-13.91-6.78-4.30
Net Income-51.37-48.44-40.38-20.95-24.98-15.83-6.44-3.66
Shares Outstanding30.2823.886.722.980.720.01--
Earnings Per Share-1.70-2.03-6.00--40.95-2,036.96-30,859.93-2,614.79
Operating Cash Flow-75.47-42.47-31.06-20.41-21.14-13.97-6.50-4.52
Capital Expenditures-1.25-5.65-2.57-1.83-0.25-0.10-0.01-
Free Cash Flow-76.72-48.12-33.62-22.24-21.39-14.07-6.50-4.52
Cash & Equivalents12112488.1214.6489.719.329.320.00
Total Debt25.010.480.890.38----
Net Cash / Debt95.6512387.2314.2689.719.329.320.00
Assets18914099.7020.0490.929.839.83-
Liabilities31.6716.2414.6611.545.902.502.50-
Book Value15712485.048.5085.02-47.95-47.95-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Synlogic, Inc.
Country United States
Employees 76
CEO Aoife M. Brennan

Stock Information

Ticker Symbol SYBX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SYBX

Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.